Erasca, Inc.
NASDAQ:ERAS · NASDAQ Global Select
-$0.02 today
Vol 7.97M · Avg 6.79M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:ERAS · Revenue to Net Income
Key Ratios
Analysis
$0 of revenue converted into -$277.0M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-0.93, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $3.1M | $0 -100.0% | $3.7M +41.3% | $2.6M +218.6% | $829.0K | $725.6M | $804.0M | $882.4M |
| Gross Profit | -$3.1M | $0 +100.0% | -$3.7M -41.3% | -$2.6M -218.6% | -$829.0K | $8.9B | $7.6B | $6.2B |
| Gross Margin | — | — | — | — | — | 9.8% | 28.9% | 38.3% |
| Research & Development | $92.9M -19.5% | $115.4M +11.1% | $103.8M -7.7% | $112.5M +52.1% | $73.9M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $38.6M -7.6% | $41.7M +10.7% | $37.7M +14.3% | $33.0M +45.9% | $22.6M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $128.3M -28.6% | $179.6M +30.3% | $137.8M -43.7% | $244.8M +97.3% | $124.1M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $3.1M -18.3% | $3.8M +2.0% | $3.7M +41.3% | $2.6M +218.6% | $829.0K | $374.2M | $1.2B | $631.8M |
| EBITDA | -$121.4M +20.8% | -$153.3M -26.4% | -$121.3M +49.5% | -$240.2M -97.0% | -$121.9M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | — | — | — | — | — | 5.6% | 46.3% | 42.0% |
| Operating Income | -$131.4M +26.8% | -$179.6M -26.9% | -$141.5M +42.8% | -$247.4M -98.1% | -$124.9M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | — | — | — | — | — | 16.6% | 24.1% | 22.0% |
| Interest Income | $16.6M -17.3% | $20.1M +20.2% | $16.7M +240.9% | $4.9M +2480.0% | $190.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 | $0 | $0 -100.0% | $201.4M | $0 | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $6.9M -61.8% | $17.9M +8.8% | $16.5M +254.9% | $4.6M +119.2% | $2.1M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$124.5M +23.0% | -$161.7M -29.3% | -$125.0M +48.5% | -$242.8M -97.8% | -$122.8M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | — | — | — | — | — | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$124.5M +23.0% | -$161.7M -29.3% | -$125.0M +48.5% | -$242.8M -97.8% | -$122.8M | $4.9B | $4.8B | $4.7B |
| Net Margin | — | — | — | — | — | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$0 +36.2% | -$1 +16.9% | -$1 +58.3% | -$2 -93.2% | -$1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$0 +36.2% | -$1 +16.9% | -$1 +58.3% | -$2 -93.2% | -$1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $283.5M +21.3% | $233.8M +55.7% | $150.2M +23.1% | $122.0M +2.5% | $119.1M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $283.5M +21.3% | $233.8M +55.7% | $150.2M +23.1% | $122.0M +2.5% | $119.1M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
ArriVent BioPharma, Inc. Common Stock
NASDAQ:AVBP
$1.49B
MoonLake Immunotherapeutics
NASDAQ:MLTX
$1.43B
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
$1.41B
Iovance Biotherapeutics, Inc.
NASDAQ:IOVA
$1.41B
MeiraGTx Holdings plc
NASDAQ:MGTX
$1.02B
Corvus Pharmaceuticals, Inc.
NASDAQ:CRVS
$1.01B
Astria Therapeutics, Inc.
ATXS
$718.13M
Valneva SE
NASDAQ:VALN
$509.01M
Arvinas, Inc.
NASDAQ:ARVN
$496.81M
CytomX Therapeutics, Inc.
NASDAQ:CTMX
$472.82M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does ERAS generate?
Erasca, Inc. (ERAS) reported $0.00 of revenue in fiscal 2025.
Is ERAS profitable?
Erasca, Inc. (ERAS) reported -$124,546,000.00 of net income.
Explore More
Continue the stock analysis
Jump to another research area for this company.